Form 8-K - Current report:
SEC Accession No. 0001641172-25-017479
Filing Date
2025-07-02
Accepted
2025-07-02 09:00:22
Documents
18
Period of Report
2025-07-02
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 44795
2 EX-3.1 ex3-1.htm EX-3.1 12945
3 EX-99.1 ex99-1.htm EX-99.1 14863
4 GRAPHIC form8-k_001.jpg GRAPHIC 5590
5 GRAPHIC ex99-1_001.jpg GRAPHIC 8561
6 GRAPHIC ex99-1_002.jpg GRAPHIC 5953
  Complete submission text file 0001641172-25-017479.txt   328910

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE cycc-20250702.xsd EX-101.SCH 3743
8 XBRL DEFINITION FILE cycc-20250702_def.xml EX-101.DEF 26581
9 XBRL LABEL FILE cycc-20250702_lab.xml EX-101.LAB 36613
10 XBRL PRESENTATION FILE cycc-20250702_pre.xml EX-101.PRE 25205
20 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5865
Mailing Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922
Business Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 908-517-7330
Cyclacel Pharmaceuticals, Inc. (Filer) CIK: 0001130166 (see all company filings)

EIN.: 911766850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-50626 | Film No.: 251098490
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)